Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFα agents failed are associated with response to rituximab in rheumatoid arthritis;La presenza del fattore reumatoide, la disabilità ed il numero di precedenti anti-TNFα falliti predicono la risposta clinica a rituximab nell'artrite reumatoide

Reumatismo

Volumn 61, Issue 3, 2009, Pages 182-186

  Quartuccio, L ^a   Salvin, S ^a   Saracco, M ^b   Lombardi, S ^a   Fabris, M ^a   Mansutti, E ^a   Maset, M ^a   Pellerito, S ^b   De Vita, Salvatore ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b Ospedale Mauriziano di Torino   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISABILITY; DRUG TREATMENT FAILURE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449516751     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kristensen LE, Kapetanovic MC, Gulfe A, Sóderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 495-499
2. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-365 (Pubitemid 34136572)
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-2806
4. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase 11B randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-1400
5. Tak PP, Cohen SB, Emery P, Saadeh CK, De Vita S, Donohue JP, et al. Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF, anti-CCP). Ann Rheum Dis 2007; 66: (Suppl 11): 338.
6. Finckh A, Ciurea A, Brulhart L, Kyburz D, Móller B, Dehler S, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007; 56: 1417-1423 (Pubitemid 46764068)
7. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46: 2029-2033 (Pubitemid 34894756)
8. Roll P, Domer T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566-1575 (Pubitemid 351847509)
9. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917-25.
10. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis. The effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008; 58: 3657-64.
11. Launois R, Payet S, Saidenberg-Kermanac'h N, Francesconi C, Franca LR, Boissier MC. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Join Bone Spine 2008; 67: 1494-1495
12. Dórner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003; 15: 246-252 (Pubitemid 36532604)
13. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167: 4710-4718 (Pubitemid 32954353)
14. Roll P, Palanichamy A, Rouziere AS, Dórner T, Kneitz C, Tony HP. B-cell regeneration after B cell depletion with rituximab in patients with rheumatoid arthritis: transient recirculation of plasmablasts and increased level of germinal center founder cell. Arthritis Rheum 2005; 52 (suppl 9): S289.
15. Leandro MJ, Cwnbridge G, Eherenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-620 (Pubitemid 43228639)
16. Rouziere AS, Kneitz C, Palanicharny A, Dómer T, Tony HP. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an antiCD20 antibody. Arthritis Res Ther 2005; 7: R714-24.
17. Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 2004; 60: 209-218 (Pubitemid 38943069)
18. Quartuccio L, Salvin S, Fabris M, Sacco S, De Vita S. Disappearance of bone marrow B-cell clonal expansion in patients with type Il HCV-related cryoglobulinemic glornerulonephritis after clinical efficient rituximab therapy. Ann Rheum Dis 2008; 67: 1494-1495
19. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004; 30: 393-403. (Pubitemid 38692569)